
Early estimates from the Centers for Disease Control (CDC) place effectiveness of the seasonal influenza vaccine at 62%.

Early estimates from the Centers for Disease Control (CDC) place effectiveness of the seasonal influenza vaccine at 62%.


The Drug Enforcement Administration (DEA) has proposed a rule that would finally make it legal for pharmacy retailers to collect and dispose of customers’ unwanted prescription medications.

The spike in flu cases over the past month, along with limited supplies of influenza vaccine and Tamiflu across the United States, has led FDA Commissioner Margaret Hamburg to issue guidance to pharmacists and other healthcare providers.

How do we empower patients who do not want drug therapy to take their routine medications? Actually, one simple tweak can make all of the difference. We tell them ‘why’ they are taking the medication.

Opioid use and physician dispensing top the list of cost drivers for workers’ compensation pharmacy programs across the country.

To help prevent opioid abuse, New York City hospitals will be limiting opioid prescriptions dispensed from its emergency departments to a three-day supply, will not be prescribing long-acting opioids, and will not be refilling lost, stolen, or destroyed prescriptions, according to new voluntary emergency room guidelines that were made available on Jan. 10.

It may seem like pharmacy has reached a very low point. One pharmacist argues that specialization could be the best way forward.

The time has come for pharmacists to be considered healthcare providers under the Social Security Act.

A survey of new Rx and generic products

Herbal supplements are quite popular among your patients, but too few pharmacists are taking the time to properly educate about the risks.

Thinking about the future of pharmacy? Remember that you serve as a role model for the next generation of pharmacists.

The FDA recently approved teriflunomide for the treatment of patients with relapsing forms of multiple sclerosis.

In between the pharmacist activities that can be easily measured, you might find yourself engaging in conversations with your patients.


Readers discuss what rights pharmacists can expect and drug disposal options.

JP spins a semi-fictional account of what is wrong with chain drug stores and mail order prescriptions.


According to a recent FDA safety announcement, varenicline may pose an increased risk of cardiovascular events.

Many of the primary care worksite health centers managed by Walgreens Employer Solutions Group have received Medical Home accreditation from the Accreditation Association for Ambulatory Health Care (AAAHC), the company recently announced.

Last month NABP Executive Director Carmen Catizone, MS, RPh, unveiled an action plan to inspect nonresident compounding pharmacies and create a database to share regulatory information about these pharmacies with the state boards of pharmacy nationwide.

Collaboration between pharmacy benefit managers and community pharmacists may improve patient compliance to vital drug regimens.

This year the National Association of Chain Drug Stores (NACDS) is offering a one-of-a-kind business opportunity by combining its three trade shows-the Marketplace Conference, the Pharmacy and Technology Conference, and the Supply Chain & Logistics Conference-into one, Total Store Expo.



After a few slow years, experts believe that there's reason to hope that 2013 might bring some recovery.

In a drug safety communication, FDA has recommended that the bedtime dose of zolpidem, for the treatment of insomnia, be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.

FDA’s recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo Pharmaceuticals), 125-mg delayed-release tablets, the first anti-diarrheal drug for HIV/AIDS patients taking antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment compliance.

FDA issued a draft guidance on Jan. 9 to help industry in the development of opioid drug formulations with abuse-deterrent properties, saying it considers development of these products a high public health priority.